Literature DB >> 22885108

Antibodies to gliomedin cause peripheral demyelinating neuropathy and the dismantling of the nodes of Ranvier.

Jérôme J Devaux1.   

Abstract

Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyneuropathy (CIDP) are conditions that affect peripheral nerves. The mechanisms that underlie demyelination in these neuropathies are unknown. Recently, we demonstrated that the node of Ranvier is the primary site of the immune attack in patients with GBS and CIDP. In particular, GBS patients have antibodies against gliomedin and neurofascin, two adhesion molecules that play a crucial role in the formation of nodes of Ranvier. We demonstrate that immunity toward gliomedin, but not neurofascin, induced a progressive neuropathy in Lewis rats characterized by conduction defects and demyelination in spinal nerves. The clinical symptoms closely followed the titers of anti-gliomedin IgG and were associated with an important deposition of IgG at nodes. Furthermore, passive transfer of antigliomedin IgG induced a severe demyelinating condition and conduction loss. In both active and passive models, the immune attack at nodes occasioned the loss of the nodal clusters for gliomedin, neurofascin-186, and voltage-gated sodium channels. These results indicate that primary immune reaction against gliomedin, a peripheral nervous system adhesion molecule, can be responsible for the initiation or progression of the demyelinating form of GBS. Furthermore, these autoantibodies affect saltatory propagation by dismantling nodal organization and sodium channel clusters. Antibodies reactive against nodal adhesion molecules thus likely participate in the pathologic process of GBS and CIDP.
Copyright © 2012 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22885108      PMCID: PMC5691341          DOI: 10.1016/j.ajpath.2012.06.034

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  43 in total

1.  Fibronectin type III-like domains of neurofascin-186 protein mediate gliomedin binding and its clustering at the developing nodes of Ranvier.

Authors:  Marilyne Labasque; Jérôme J Devaux; Christian Lévêque; Catherine Faivre-Sarrailh
Journal:  J Biol Chem       Date:  2011-10-17       Impact factor: 5.157

2.  CNS myelin paranodes require Nkx6-2 homeoprotein transcriptional activity for normal structure.

Authors:  Cherie Southwood; Chris He; James Garbern; John Kamholz; Edgardo Arroyo; Alexander Gow
Journal:  J Neurosci       Date:  2004-12-15       Impact factor: 6.167

3.  Synergy between antibody and P2-reactive T cells in experimental allergic neuritis.

Authors:  J M Spies; J D Pollard; J G Bonner; K W Westland; J G McLeod
Journal:  J Neuroimmunol       Date:  1995-03       Impact factor: 3.478

4.  Guillain-Barré syndrome: an ultrastructural study of peripheral nerve in 65 patients.

Authors:  C Brechenmacher; C Vital; C Deminiere; L Laurentjoye; Y Castaing; G Gbikpi-Benissan; J P Cardinaud; J P Favarel-Garrigues
Journal:  Clin Neuropathol       Date:  1987 Jan-Feb       Impact factor: 1.368

5.  Role of therapeutic plasmapheresis in the acute Guillain-Barré syndrome.

Authors:  G M McKhann; J W Griffin; D R Cornblath; S A Quaskey; E D Mellits
Journal:  J Neuroimmunol       Date:  1988-12       Impact factor: 3.478

6.  Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  J R Mendell; R J Barohn; M L Freimer; J T Kissel; W King; H N Nagaraja; R Rice; W W Campbell; P D Donofrio; C E Jackson; R A Lewis; M Shy; D M Simpson; G J Parry; M H Rivner; C A Thornton; M B Bromberg; R Tandan; Y Harati; M J Giuliani
Journal:  Neurology       Date:  2001-02-27       Impact factor: 9.910

7.  Gliomedin mediates Schwann cell-axon interaction and the molecular assembly of the nodes of Ranvier.

Authors:  Yael Eshed; Konstantin Feinberg; Sebastian Poliak; Helena Sabanay; Offra Sarig-Nadir; Ivo Spiegel; John R Bermingham; Elior Peles
Journal:  Neuron       Date:  2005-07-21       Impact factor: 17.173

Review 8.  Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome.

Authors:  Pieter A van Doorn; Liselotte Ruts; Bart C Jacobs
Journal:  Lancet Neurol       Date:  2008-10       Impact factor: 44.182

Review 9.  Molecular mechanisms of node of Ranvier formation.

Authors:  Keiichiro Susuki; Matthew N Rasband
Journal:  Curr Opin Cell Biol       Date:  2008-11-01       Impact factor: 8.382

10.  Sural nerve biopsies in Guillain-Barre syndrome: axonal degeneration and macrophage-associated demyelination and absence of cytomegalovirus genome.

Authors:  R Hughes; P Atkinson; P Coates; S Hall; S Leibowitz
Journal:  Muscle Nerve       Date:  1992-05       Impact factor: 3.217

View more
  22 in total

Review 1.  The Nodes of Ranvier: Molecular Assembly and Maintenance.

Authors:  Matthew N Rasband; Elior Peles
Journal:  Cold Spring Harb Perspect Biol       Date:  2015-09-09       Impact factor: 10.005

2.  Long-term maintenance of Na+ channels at nodes of Ranvier depends on glial contact mediated by gliomedin and NrCAM.

Authors:  Veronique Amor; Konstantin Feinberg; Yael Eshed-Eisenbach; Anya Vainshtein; Shahar Frechter; Martin Grumet; Jack Rosenbluth; Elior Peles
Journal:  J Neurosci       Date:  2014-04-09       Impact factor: 6.167

Review 3.  Subcutaneous immunoglobulins in the treatment of chronic immune-mediated neuropathies.

Authors:  Verena I Leussink; Hans-Peter Hartung; Bernd C Kieseier; Mark Stettner
Journal:  Ther Adv Neurol Disord       Date:  2016-04-06       Impact factor: 6.570

Review 4.  Autoimmune antigenic targets at the node of Ranvier in demyelinating disorders.

Authors:  Panos Stathopoulos; Harry Alexopoulos; Marinos C Dalakas
Journal:  Nat Rev Neurol       Date:  2015-01-27       Impact factor: 42.937

Review 5.  Animal models of autoimmune neuropathy.

Authors:  Betty Soliven
Journal:  ILAR J       Date:  2014

6.  The Transcription Factors EBF1 and EBF2 Are Positive Regulators of Myelination in Schwann Cells.

Authors:  Diego Moruzzo; Lucilla Nobbio; Bruno Sterlini; G Giacomo Consalez; Fabio Benfenati; Angelo Schenone; Anna Corradi
Journal:  Mol Neurobiol       Date:  2016-11-26       Impact factor: 5.590

7.  The olfactomedin domain from gliomedin is a β-propeller with unique structural properties.

Authors:  Huijong Han; Petri Kursula
Journal:  J Biol Chem       Date:  2014-12-17       Impact factor: 5.157

8.  Expression, purification, crystallization and preliminary X-ray crystallographic analysis of the extracellular olfactomedin domain of gliomedin.

Authors:  Huijong Han; Petri Kursula
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2014-10-25       Impact factor: 1.056

9.  Survival among children with "Lethal" congenital contracture syndrome 11 caused by novel mutations in the gliomedin gene (GLDN).

Authors:  Jennifer A Wambach; Georg M Stettner; Tobias B Haack; Karin Writzl; Andreja Škofljanec; Aleš Maver; Francina Munell; Stephan Ossowski; Mattia Bosio; Daniel J Wegner; Marwan Shinawi; Dustin Baldridge; Bader Alhaddad; Tim M Strom; Dorothy K Grange; Ekkehard Wilichowski; Robin Troxell; James Collins; Barbara B Warner; Robert E Schmidt; Alan Pestronk; F Sessions Cole; Robert Steinfeld
Journal:  Hum Mutat       Date:  2017-08-17       Impact factor: 4.878

10.  Specific contactin N-glycans are implicated in neurofascin binding and autoimmune targeting in peripheral neuropathies.

Authors:  Marilyne Labasque; Bruno Hivert; Gisela Nogales-Gadea; Luis Querol; Isabel Illa; Catherine Faivre-Sarrailh
Journal:  J Biol Chem       Date:  2014-02-04       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.